 |
Case Report
Complete response of metastatic cervical adenocarcinoma treated with chemoradiotherapy followed by pembrolizumab: A case report
1 Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA
2 University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA
3 Associated Pathologists Chartered Laboratories, American Melanoma Institute, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA
Address correspondence to:
Wolfram Samlowski
MD, Comprehensive Cancer Centers of Nevada, 9280 W. Sunset Rd, Suite 100, Las Vegas, NV 89148,
USA
Message to Corresponding Author
Article ID: 100078Z10WS2021
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Samlowski W, Chang M, Meoz R, Hedayat A. Complete response of metastatic cervical adenocarcinoma treated with chemoradiotherapy followed by pembrolizumab: A case report. J Case Rep Images Oncology 2021;7:100078Z10WS2021.ABSTRACT
Introduction: Metastatic adenocarcinoma of the uterine cervix is challenging to treat, particularly if there is persistent disease following surgery and chemoradiotherapy. In recent years, advances in checkpoint inhibitor-based immunotherapy have shown promise in patients in a variety of cancers. Only limited information is available concerning treatment of cervical adenocarcinoma with checkpoint inhibitors.
Case Report: This case report details a patient with metastatic cervical adenocarcinoma with persistent disease following surgical resection. Subsequent treatment with cisplatin, paclitaxel, and bevacizumab therapy with concurrent radiotherapy resulted in a partial response. The patient was subsequently treated with pembrolizumab. After 3 cycles of treatment the patient achieved a stable radiologic complete remission, which continues after treatment discontinuation.
Conclusion: This result suggests that chemoradiotherapy with either concurrent or sequential administration of a PD-1 antibody, such as pembrolizumab, may have significant activity as treatment of metastatic or unresectable cervical adenocarcinoma. Further prospective clinical testing appears warranted.
Keywords: Cervical adenocarcinoma, Cervix cancer, Checkpoint inhibitor, Chemoradiotherapy, Pembrolizumab
SUPPORTING INFORMATION
Acknowledgments
We thank the clinic nursing and pharmacy staff at Comprehensive Cancer Centers of Nevada for their assistance in this patient’s care.
Author ContributionsWolfram Samlowski - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Mark Chang - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Raul Meoz - Acquisition of data, Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Amin Hedayat - Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2021 Wolfram Samlowski et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
